Не сдохни! Еда в борьбе за жизнь

^{‹‹69››.} Cardiogenic Dementia. Lancet. 1977;1(8001):27–8.

^{‹‹70››.} Roher AE, Tyas SL, Maarouf CL, et al. Intracranial atherosclerosis as a contributing factor to Alzheimer’s disease dementia. Alzheimers Dement. 2011;7(4):436–44.

^{‹‹71››.} Roher AE, Tyas SL, Maarouf CL, et al. Intracranial atherosclerosis as a contributing factor to Alzheimer’s disease dementia. Alzheimers Dement. 2011;7(4):436–44.

^{‹‹72››.} Yarchoan M, Xie SX, Kling MA, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain. 2012;135(Pt 12):3749–56.

^{‹‹73››.} Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer’s Coordinating Center. Neurology. 2005;64(3):494–500.

^{‹‹74››.} de la Torre JC. Vascular risk factors: a ticking time bomb to Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2013;28(6):551–9.

^{‹‹75››.} Roher AE, Tyas SL, Maarouf CL, et al. Intracranial atherosclerosis as a contributing factor to Alzheimer’s disease dementia. Alzheimers Dement. 2011;7(4):436–44.

^{‹‹76››.} de la Torre JC. Vascular basis of Alzheimer’s pathogenesis. Ann N Y Acad Sci. 2002;977:196–215.

^{‹‹77››.} Zhu J, Wang Y, Li J, et al. Intracranial artery stenosis and progression from mild cognitive impairment to Alzheimer disease. Neurology. 2014;82(10):842–9.

^{‹‹78››.} Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology. 2009;73(9):674–80.

^{‹‹79››.} Mizuno T, Nakata M, Naiki H, et al. Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture. J Biol Chem. 1999;274(21):15110–4.

^{‹‹80››.} Trumbo PR, Shimakawa T. Tolerable upper intake levels for trans fat, saturated fat, and cholesterol. Nutr Rev. 2011;69(5):270–8.

^{‹‹81››.} Benjamin MM, Roberts WC. Facts and principles learned at the 39th Annual Williamsburg Conference on Heart Disease. Proc (Bayl Univ Med Cent). 2013;26(2):124–36.

^{‹‹82››.} Corsinovi L, Biasi F, Poli G, et al. Dietary lipids and their oxidized products in Alzheimer’s disease. Mol Nutr Food Res. 2011;55 Suppl 2:S161–72.

^{‹‹83››.} Harris JR, Milton NGN. Cholesterol in Alzheimer’s disease and other amyloidogenic disorders. Subcell Biochem. 2010;51:47–75.

^{‹‹84››.} Puglielli L, Tanzi RE, Kovacs DM. Alzheimer’s disease: the cholesterol connection. Nat Neurosci. 2003;6(4):345–51.

^{‹‹85››.} Harris JR, Milton NGN. Cholesterol in Alzheimer’s disease and other amyloidogenic disorders. Subcell Biochem. 2010;51:47–75.

^{‹‹86››.} Reed B, Villeneuve S, Mack W, et al. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 2014;71(2):195–200.

^{‹‹87››.} US Food and Drug Administration. Important safety label changes to cholesterol-lowering statin drugs. Silver Spring, MD: US Department of Health and Human Ser vices; 2012. http://www.fda.gov/Drugs/ DrugSafety/ucm293101.htm. July 7, 2012. Accessed April 2, 2015.

^{‹‹88››.} Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother. 2012;46(4): 549–57.